Funded Startups in North Brunswick
Five companies appear in the North Brunswick slice, with disclosed funding amounts clustering in the low single-digits to the tens of millions.
Five companies appear in the North Brunswick slice, with disclosed funding amounts clustering in the low single-digits to the tens of millions. The largest disclosed round is PDS Biotechnology Corporation’s $25M post-IPO debt on 2022-08-24, which is the only disclosed figure in the $20M+ range; the other disclosed rounds shown are $5M (Fidelis Pharmaceuticals, 2021-07-21) and $3M (Ascendia Pharmaceuticals, 2024-10-11), while two entries are undisclosed (AssetIntel on 2026-06-16; Orthobond on 2024-09-09). Sector-wise, biotechnology is the most common: three of the five companies are listed as Biotechnology (Orthobond, Ascendia Pharmaceuticals, PDS Biotechnology Corporation), with Fidelis Pharmaceuticals also tied to Health Care and AssetIntel tied to Financial Services.
Dates span from 2021-07-21 (Fidelis Pharmaceuticals) through 2026-06-16 (AssetIntel). A tight biotech window appears in 2024: Ascendia Pharmaceuticals ($3M) on 2024-10-11 and Orthobond (undisclosed) on 2024-09-09 sit within about a month of each other, despite the remaining rounds being spaced farther apart.
Most recent rounds
5 shownRelated listings
Frequently asked
Are there outliers that merit a closer look beyond biotech?
AssetIntel is the main outlier by sector, listed under Financial Services and dated 2026-06-16 with an undisclosed amount, whereas the other four companies are Health Care or Biotechnology and include disclosed funding on 2021-07-21 ($5M), 2022-08-24 ($25M), and 2024-10-11 ($3M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.